Wednesday, July 2, 2025 7/2/2025

Mapping the regulatory landscape of RNA binding proteins and their causal roles in tumorigenesis and patient survival

Award Number: R01CA257153
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/12/2021
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Mapping the regulatory landscape of RNA binding proteins and their causal roles in tumorigenesis and patient survival - Summary Our preliminary results support a prominent role for dysregulation of RNA binding proteins (RBPs) in cancer progression. In fact, our analysis of the cancer genome atlas (TCGA) transcriptome data shows that RBPs, as a group, are significantly more dysregulated in cancer than transcription factors. We propose a multi-faceted set of computational and experimental studies to systematically identify the set of RBPs that causally contribute to cancer progression and to characterize their downstream effector mechanisms. In one strategy, we propose to identify dysregulated RBPs by first discovering their cis-regulatory recognition elements in the 3’ and 5’ UTR of genes that show dynamic mRNA expression—both between tumor vs. normal samples, and across each of the 25 cancer cohorts in TCGA. This will be accomplished using information-theoretic algorithms that discover de novo linear and structural RNA motif elements with high sensitivity and low false discovery rates. We have previously shown that such RNA motifs are the binding sites for RBPs that modulate mRNA stability, a subset of which regulate tumorigenesis and metastasis. The genes harboring these motifs constitute an orphan RBP regulon (or RBP module) with a suspected role in cancer progression. In order to identify clinically significant RBP modules, we propose to develop a computational framework that quantifies the degree to which the expression of each module stratifies patient survival across the TCGA primary tumor samples. Our preliminary results have led to the discovery of many such modules with remarkable stratification of patient survival across multiple cancer types. For the subset of the most clinically prognostic modules, we will identify their cognate RBPs using both biochemical and CRISPR-based parallel genetic screens. In a complementary strategy, we will computationally identify such clinically prognostic RBP modules from a compendium of ENCODE transcriptome data obtained following shRNA knockdowns of each of ~250 RBPs. In order to identify RBPs that causally contribute to cancer progression, we propose to develop a parallel CRISPR loss-of-function screen for all RBPs in mouse xenograft models of tumor formation and metastasis. We will then conduct a more focused CRISPR screen on the top ~20 RBPs that show both significant patient survival stratification and mouse in vivo tumor effects in our primary comprehensive screen. The top validated RBPs will then be individually characterized for their roles in a variety of in vitro and in vivo cancer cell phenotypes. Finally, we propose to develop a parallel mouse in vivo CRISPR epistasis platform to efficiently determine the specific downstream genes through which the RBP exerts its effects on tumor formation and metastasis. Our integrated computational/experimental strategy will expand our molecular understanding of a largely unexplored domain of cancer pathway dysregulation and potentially reveal new principles at work. Furthermore, our focus on causal pathways of cancer progression will impact the diagnostic, prognostic, and therapeutic precision with which we approach clinical oncology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $532,716 )
2025	2025	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	001	5	6/23/2025	NON-COMPETING CONTINUATION	$53,272
2025	2025	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	000	5	1/15/2025	NON-COMPETING CONTINUATION	$479,444
														Subtotal = $532,716

Issue Date FY: 2024 ( Subtotal = $338,430 )
2024	2024	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	001	4	5/6/2024	NON-COMPETING CONTINUATION	$27,360
2024	2024	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	000	4	3/13/2024	NON-COMPETING CONTINUATION	$311,070
														Subtotal = $338,430

Issue Date FY: 2023 ( Subtotal = $536,228 )
2023	2023	TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	000	3	1/30/2023	NON-COMPETING CONTINUATION	$536,228
														Subtotal = $536,228

Issue Date FY: 2022 ( Subtotal = $536,231 )
2022	2022	TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	001	2	5/4/2022	NON-COMPETING CONTINUATION	$43,774
2022	2022	TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	000	2	1/12/2022	NON-COMPETING CONTINUATION	$492,457
														Subtotal = $536,231

Issue Date FY: 2021 ( Subtotal = $562,675 )
2021	2021	TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE	630 W 168TH ST FL 4	NEW YORK	NY	10032	NEW YORK	USA	Cancer Cause and Prevention Research	000	1	2/12/2021	NEW	$562,675
														Subtotal = $562,675

Grand Total All Awards = $2,506,280

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mapping the regulatory landscape of RNA binding proteins and their causal roles in tumorigenesis and patient survival

Award Number: R01CA257153

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/12/2021

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer